Begin main content

Trifluridine-Tipiracil (Lonsurf) for Gastric Cancer — Details

Project Number pCODR 10197
Brand Name Lonsurf
Generic Name Trifluridine-Tipiracil
Tumour Type Gastrointestinal
Indication Gastric Cancer
Funding Request For the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease
Review Status Under Review
Pre Noc Submission Yes
NOC Date
Manufacturer Taiho Pharma Canada, Inc.
Sponsor Taiho Pharma Canada, Inc.
Submission Date September 3, 2019
Submission Deemed Complete September 17, 2019
Submission Type New Indication
Prioritization Requested
Stakeholder Input Deadline ‡ September 17, 2019
Check-point meeting (target date) November 6, 2019
pERC Meeting (target date)
Initial Recommendation Issued (target date)
Feedback Deadline (target date) ‡
pERC Reconsideration Meeting (target date)
Final Recommendation Issued (target date)
Notification to Implement Issued

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.